Skip to main content
Fig. 5 | Molecular Medicine

Fig. 5

From: Protection Against Hyperacute Xenograft Rejection of Transgenic Rat Hearts Expressing Human Decay Accelerating Factor (DAF) Transplanted into Primates

Fig. 5

In vitro protection of ECs isolated from transgenic rats against primate xenogeneic antibodies and complement-mediated cell lysis.

Cardiac ECs from wild-type (WT) and transgenic, either hemizygous (DAF+/−) or homozygous (DAF+/+), rats were labeled with Cr51 and incubated for 4 hr at 37°C with serial dilutions (from 25% to 6.12%, 50 µl/well) of cynomolgus serum. Cell lysis was determined by measuring Cr51 release in culture supernatant as described in Materials and Methods. All experiments were done in triplicate, and the results are expressed as the mean of percent specific lysis ± SD values. Results are representative of three independent experiments.

Back to article page